Ms Indu Soni
45-year-old Female from New Delhi, Diagnosed with Bilateral Ovarian Carcinoma with Peritoneal and Lymph node metastasis. Came to us In March-2021, post-surgery (Total Abdominal Hysterectomy with Bilateral salpingo-oophorectomy). Her ECOG performance status was 1. She was administered DENVAX, a Dendritic Cell-based autologous Cancer Immunotherapy total of 25 doses (23 intravenous doses and 2 cycles of Local dose) at 15- 21 days intervals, along with low-dose chemotherapy (Gemcitabine & Bevacizumab 9 cycles and also paclitaxel). Her health improved during the course of the treatment, along with weight gain. Her PET CT scan on June-22 reveals near complete Resolution. The patient is symptom-free and in good health.
CANCER BREAST TREATMENT
A 35-year old female, diagnosed of triple-negative breast cancer, consulted Dr. Khan who advised her surgery. From May 2013 onwards, she was given Denvax along with 3 cycles of low dose chemotherapy. She has since then developed no relapse and is till date, disease-free. She continues to go to her job and enjoys a good quality of life. Her PET CT done recently shows no disease.
LIVER CANCER
A young female consulted me in late 2014. She had a history of HCC (Hepatocellular carcinoma) with Hepatitis B positive status, with resection performed in early 2014. Gradually she progressed with disease. When she came to our clinic she had weakness and lethargy. Her PET-CT indicated disease in the liver and lungs. Her lab parameters were deranged but serum bilirubin was within normal limits. She was put on Denvax, dendritic cell therapy, and within three months of therapy she started showing signs of improvement. Her latest PET-CT done this month has shown complete resolution of the disease. Additionally, her hepatitis B test has become negative. Nothing of this sort has ever been reported in the medical literature.
Mr Rajender Singh
A 54-year-old male from Sonipat, Diagnosed with Metastatic carcinoma colon. The patient was operated on (Radical sigmoid Colectomy) in Dec-2020, which was followed by 8 cycles of chemotherapy (FOLFIRI). Came to us in February 2021 with stage 4 disease with weight loss & cachexia. He was administered DENVAX, a Dendritic Cell-based Autologous Intravenous Cancer Immunotherapy total of 15 doses at 15-21 days intervals, along with an immune checkpoint inhibitor (Nivolumab) at a monthly interval total of 12 doses. His overall health improved with time along with weight gain. His recent PET CT scan (Nov-22) reveals complete Metabolic Resolution. The patient is symptom-free and in good health.
SARCOMA OF TIBIA WITH LUNG METASTASIS
A 46-year-old male diagnosed with sarcoma of the tibia (left leg bone) with lung secondary presented in November 2009 for dendritic cell therapy. He was operated earlier, and had received chemotherapy and radiation therapy. His disease was progressing with all the above methods.
He was advised and put on DENVAX. He completed his six doses in April 2010. He regained his health and was back to his normal life. He started to work again. There was a progression free interval of one year. His disease resurfaced in April 2011 with complaints of cough and a Chest CT showing disease progression. He has again been advised dendritic cell therapy along with chemotherapy. He has shown response by showing no adverse effects of chemotherapy as well as symptoms subsiding.
MULTIPLE MYELOMA
A 48-year-old bed-ridden male patient, suffering from multiple myeloma with recurrent-urinary infection came to us in June 2006. His disease progressed from solitary plasmacytoma to multiple myeloma over a period of three years. During this period, he received various cycles of chemotherapy and pelvic radiation. He was also operated upon for fracture of neck femur. His IgG was 4500 mg/dL at that time. Bone scan revealed multiple active sites all along the spine and pelvic girdle. His performance status was poor and there were no active regimes of chemotherapy available at that stage. We started giving him Dendritic cell cancer vaccine manufactured using his M band protein content as antigen processed in our lab. He received eight doses of DC cancer vaccines till September of 2007. For the last one year, he was able to walk a few steps, take bath on his own, and his performance status had improved. His recent bone scan indicated regression of disease. There was benefit both, in survival and quality of life. The patient ceases to survive.
OVARIAN CANCER TREATMENT
A 58-year-old lady was diagnosed of cancer ovary in June 2004. Her CA 125 antigen marker was positive and in the range of 10,000 units. She was operated upon and given six cycles of chemotherapy. She recovered from her disease and her marker was also within normal range. After one year, the CA 125 began rising and she presented to us with an increased titre of 400 units. There were signs of recurrence, and she opted for DC (DENVAX) therapy in June 2005. She has completed three years of receiving DENVAX. She is free of disease, proven both clinically and by radiological examinations. Her CA 125 marker is also stable for the last three years.We have done series of ovarian cancer patients and the presentation is available in publications section of our webpages.
NON HODGKINS LYMPHOMA
A 46-year-old male was operated for mediastinal tumor in 2010. It was diagnosed as T-cell lymphoma (Lymphoblastic Lymphoma). He started his treatment with chemotherapy. Each time he had to be admitted for managing the complications of chemotherapy. He was losing weight and appetite and having erosions of mucosal membrane. He required G-CSF injections along with antibiotics and lots of IV fluids to maintain his cell counts and nutrition. He was unable to tolerate 4th dose of chemotherapy when he consulted his oncologist to combine chemotherapy with dendritic cell therapy. During the course of conventional treatment, he received mediastinal radiation also for 4 weeks. The oncologist accepted the protocol and the chemotherapy was combined with DENVAX cell therapy doses that concluded in six months (from November 2010 to April 2011).
With this combined approach he stopped developing the post-chemotherapy complication. The patient suffered no chemo-related adverse effects contrary to the earlier findings. He has improved in performance status and is working in his office without taking a day-off from work. He is having regular follow ups and is free of disease as confirmed by his PET-CT in January 2011.
RENAL CANCER
A 60-year-old female presented with metastatic clear cell carcinoma of kidney in December 2007. Her right kidney was excised and subjected to histopathology examination. It revealed pathological stage TNM- pT3 N1 M1. Her complaints were pain in abdomen and frequent urination. She presented with weight loss and anemia.
She was given the option of DENVAX, dendritic cell-based immunotherapy. She received five doses at monthly interval. In three doses, her complaints began to resolve and was back to her normal self in five doses. Intermittently, she continued to receive DENVAX therapy.
She was again evaluated in March 2011 for routine check up and was further advised to received additional DC therapies. Her reports indicate no active disease. Overall her health is good and she does all her normal activities without any assistance.
She is completing 4 years of her quality life without receiving chemotherapy, monoclonal antibodies or interferons and is maintained on dendritic cell therapy.
LUNG CANCER TREATMENT
A 68-year-old lady came to us in December 2005 with left lobe Large cell cancer of the lung with pleural effusion from the same side. She had till then received a single dose of chemotherapy and had refused further doses. Pleural tapping was done and her TAA was identified and stored for DC vaccine preparation. She received 9 doses of DC therapy in a 9-month period. Her PFT improved and also the performance status. CECT remained unremarkable. The pleural fluid was replaced by consolidation. The tumor has not progressed since then and there is no evidence of metastasis to any organ. The cancer patient is surviving and is no more receiving DC vaccines. She is now on immunotherapy for the last 12 months.
Mr Izhar Ahmed
50yr old male from Kolkata was diagnosed with carcinoma oral cavity with cervical lymph nodes metastasis. Consulted us in October 2021 post 20 sessions of radiotherapy and oral chemotherapy (methotrexate and erlotinib). The patient's ECOG performance status was 0. He was administered DENVAX, Dendritic Cell-based Autologous Cancer Immunotherapy both intravenous and intralesional total of 18 doses (14 Intravenous doses & 4 cycles of intralesional doses) along with low-dose chemotherapy (6 cycles of Gemcitabine and 6 cycles of Cisplatin & 5-FU) in the initial phase of treatment. His lesion improved during the course of the therapy. His 2 consecutive PET CT scan 3 months apart (Aug-22 and Nov-22) show complete resolution. The patient is symptom-free and in good health.
